In 532 patients with HFrEF (NYHA II–III, LVEF ≤35%), vagal nerve stimulation vs control did not significantly reduce cardiovascular death or HF hospitalisation (HR 0.84; 95% CI 0.62–1.12) in a trial stopped early by the sponsor; 96.7% were free of device-related serious events.
RCTn = 532
Konstam et al. Vagal Nerve Stimulation in Patients With Heart Failure and Reduced Ejection Fraction: The ANTHEM-HFrEF Trial